
BMO Capital has decided to maintain its Outperform rating of C4 Therapeutics (NASDAQ:CCCC) and lower its price target from $57.00 to $20.00.
Shares of C4 Therapeutics are trading down 20.49% over the last 24 hours, at $9.00 per share.

BMO Capital has decided to maintain its Outperform rating of C4 Therapeutics (NASDAQ:CCCC) and lower its price target from $57.00 to $20.00.
Shares of C4 Therapeutics are trading down 20.49% over the last 24 hours, at $9.00 per share.